FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity

por Jennifer Abuzzahab, M, Shoemaker, Ashley, Gottschalk, Michael, Miller, Jennifer, Yuan, Guojun, Malhotra, Sonali, Scimia, Cecilia, Roth, Christian L
Publicado 2023

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial

por Roth, Christian L, Shoemaker, Ashley H, Gottschalk, Michael, Miller, Jennifer, Yuan, Guojun, Malhotra, Sonali, Scimia, Cecilia, Jennifer Abuzzahab, M
Publicado 2023

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity

por Roth, Christian L, Shoemaker, Ashley H, Gottschalk, Michael, Miller, Jennifer, Yuan, Guojun, Malhotra, Sonali, Scimia, Cecilia, Jennifer Abuzzahab, M
Publicado 2023

FRI065 Trial Design Of A Double-blind, Randomized, Placebo-controlled, Phase 3 Study Of Setmelanotide In Patients With Hypothalamic Obesity

por Roth, Christian L, Shoemaker, Ashley H, Gottschalk, Michael, Miller, Jennifer L, Yuan, Guojun, Malhotra, Sonali, Scimia, Cecilia, McCormack, Shana, Jennifer Abuzzahab, M
Publicado 2023